Fractyl Health reported one‑year data from the REMAIN‑1 Midpoint Cohort showing that a single endoscopic duodenal ablation procedure, the Revita DMR System, was associated with reduced weight regain after discontinuation of GLP‑1 receptor agonist therapy compared with a sham procedure.
Key findings from the randomized midpoint cohort
In the modified intention‑to‑treat population (N = 45), participants who underwent the Revita procedure experienced a lower estimated mean percentage of weight regain at one year than those randomized to sham: 7.8% versus 13.0% of body weight, respectively. The company reported this as approximately a 40% reduction in weight regain versus sham (Revita n = 29, sham n = 16).
Effects were larger in groups that received more extensive duodenal ablation. Among participants with complete ablation (> 14 cm), Revita recipients maintained roughly 81% of prior GLP‑1–induced weight loss at one year compared with 48% for sham, corresponding to estimated mean weight regain of 4.8% versus 13.0% of body weight (Revita n = 17, sham n = 16).
An optimized subgroup — participants with complete ablation and higher run‑in GLP‑1 weight loss (≥ 17.5%) — showed the greatest preservation: about 84% of GLP‑1–induced weight loss maintained at one year (Revita n = 10, sham n = 8).
What the data mean and their limitations
These results are exploratory and come from a midpoint cohort not powered for formal statistical inference. The company framed the outcomes as reinforcing a dose‑dependent effect — that is, more extensive duodenal ablation correlated with greater durability of weight maintenance after stopping GLP‑1 treatment.
Important context for clinicians and patients: GLP‑1 receptor agonists have transformed obesity care by producing substantial weight loss for many people, but weight regain after discontinuation is common. The REMAIN‑1 data suggest a procedural approach may reduce the extent of regain, particularly when the ablation is more complete and when patients achieved larger initial weight loss on GLP‑1s.
Numeric summary
| Population | Revita mean regain (%) | Sham mean regain (%) | Revita n | Sham n |
|---|---|---|---|---|
| mITT overall (N=45) | 7.8 | 13.0 | 29 | 16 |
| Complete ablation >14 cm | 4.8 | 13.0 | 17 | 16 |
| Optimized (complete ablation & ≥17.5% run‑in loss) | — (maintained ~84% of prior loss) | — (maintained ~16% of prior loss) | 10 | 8 |
Implications and next steps
- The results support further study of duodenal mucosal resurfacing as a potential adjunct to pharmacologic obesity therapies for sustaining weight loss after medication discontinuation.
- Because the analysis is exploratory and the cohort modest in size, larger, adequately powered trials will be needed to confirm efficacy and safety and to define which patients might benefit most.
- Regulatory review and broader clinical adoption would require replication of these findings, longer follow‑up and careful assessment of procedure‑related risks compared with medical management alone.
The REMAIN‑1 midpoint cohort adds to a growing body of research exploring how endoscopic and other procedural approaches might complement drug treatments in obesity and type 2 diabetes. These findings are preliminary; clinicians and patients should interpret them in the context of trial limitations and await full peer‑reviewed data and regulatory guidance.
